Trial Profile
A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2017
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Cisplatin; Paclitaxel
- Indications Head and neck cancer
- Focus Therapeutic Use
- Sponsors Guangzhou Double Bioproducts
- 18 Dec 2015 New trial record